Literature DB >> 17467891

Atherothrombotic ischemic stroke in patients with atrial fibrillation.

Gulcin Benbir1, Derya Uluduz, Birsen Ince, Melda Bozluolcay.   

Abstract

OBJECTIVES: About one in five patients with atrial fibrillation have significant carotid artery disease, but not all strokes are cardioembolic in origin in these patients.
PURPOSE: We investigated stroke sub-types based mainly on clinical, carotid ultrasonographic, and neuroimaging findings in ischemic stroke patients with non-valvular atrial fibrillation (NVAF). PATIENTS AND METHODS: The etiology of stroke was classified as definite or probable cardioembolic, possible lacunar, or possible atherothrombotic, as proposed by Hart et al. and the TOAST criteria. Clinical features and risk factors (gender, age, diabetes mellitus, hypertension, hyperlipidemia, cigarette smoking, and alcohol consumption) were designated as clinical variables.
RESULTS: One hundred and six of 1938 patients (5.5%) had NVAF. In patients with and without NVAF, hyperlipidemia was more common in patients without NVAF (p<0.001), while the prevalence of other risk factors was not statistically different. On the basis of the TOAST criteria, none of the patients with NVAF could be classified as having had an atherothrombotic stroke. According to the classification by Hart et al., of the patients with NVAF, 49 patients (46.3%) had a definite embolic stroke, 17 (16.0%) had a probable embolic stroke, 12 (11.3%) had a possible atherothrombotic stroke, 17 (16.0%) had a possible lacunar infarction, and 11 (10.4%) had a stroke of undetermined etiology. Besides the presence of significant carotid stenosis (p<0.001), none of the variables related to stroke were different among the sub-groups.
CONCLUSION: Patients with significant carotid stenosis were more likely to develop atherothrombotic stroke, while other risk factors associated with stroke failed to point to an etiologic cause. It should also be emphasized that the conventional classification system failed to aid in the correct diagnosis and risk stratification in patients with multiple confounding risk factors.

Entities:  

Mesh:

Year:  2007        PMID: 17467891     DOI: 10.1016/j.clineuro.2007.03.009

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  6 in total

1.  Cardiovascular fitness training for a patient in the early stages of recovery post stroke.

Authors:  Marilyn Mackay-Lyons; Marianne Thornton; Alison Macdonald
Journal:  Physiother Can       Date:  2011-08-10       Impact factor: 1.037

2.  Is there a role for new oral anticoagulants as primary and secondary stroke prevention in atrial fibrillation and intracranial stenosis?

Authors:  Claudia Stöllberger; Adam Bastovansky; Josef Finsterer
Journal:  J Thromb Thrombolysis       Date:  2013-11       Impact factor: 2.300

Review 3.  Direct oral anticoagulants in the secondary prevention of stroke and transient ischemic attack in patients with atrial fibrillation.

Authors:  Valentina Arnao; Giancarlo Agnelli; Maurizio Paciaroni
Journal:  Intern Emerg Med       Date:  2015-04-11       Impact factor: 3.397

Review 4.  The challenge of antiplatelet therapy in patients with atrial fibrillation and heart failure.

Authors:  Yutao Guo; Gregory Y H Lip; Stavros Apostolakis
Journal:  J Cardiovasc Transl Res       Date:  2012-12-04       Impact factor: 4.132

5.  Clinical and Imaging Characteristics of Cerebral Infarction in Patients with Nonvalvular Atrial Fibrillation Combined with Cerebral Artery Stenosis.

Authors:  Wei Sun; Guangsheng Li; Xiangjun Zeng; Zhaohui Lai; Mingqi Wang; Yi Ouyang; Guoyong Zeng; Jidong Peng; Junyuan Zhong; Daoxiong Xiao; Zhiping Huang; Xiaofen Guo
Journal:  J Atheroscler Thromb       Date:  2018-06-05       Impact factor: 4.928

6.  The association of CHA2DS2-VASc score and carotid plaque in patients with non-valvular atrial fibrillation.

Authors:  Luxiang Shang; Yang Zhao; Mengjiao Shao; Huaxin Sun; Min Feng; Yaodong Li; Xianhui Zhou; Baopeng Tang
Journal:  PLoS One       Date:  2019-02-08       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.